Navigation Links
Sangamo BioSciences to Acquire Ceregene
Date:8/26/2013

RICHMOND, Calif., Aug. 26, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.  Sangamo will host a teleconference at 8:30 am ET tomorrow, Tuesday, August 27, 2013, to discuss the acquisition and provide a general business overview.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

"Ceregene is a leader in development and manufacturing of AAV-based therapies with significant clinical development experience," said Edward Lanphier, Sangamo's president and CEO.  "Since their inception in 2001, the company has safely treated over 115 subjects in four clinical trials. Sangamo has acquired all of Ceregene's AAV assets including CERE-110, AAV delivery of nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease.  CERE-110 is being evaluated in a fully enrolled and fully funded Phase 2 clinical trial. In addition to the AAV platform, the assets also include one of the world's largest databases of AAV GMP manufacturing know-how, toxicology data, and safety data from their human clinical trials, which will be an invaluable resource as we advance our ZFP Therapeutics."

Under the terms of the definitive agreement Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, which represents less than 0.2 percent of Sangamo's total shares outstanding.  In addition, Sangamo has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene.  The acquisition is
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
2. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
3. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
4. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
5. Sangamo BioSciences Reports First Quarter 2013 Financial Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
9. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
10. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
11. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... DIEGO, July 29, 2015 Neurocrine Biosciences, Inc. (NASDAQ: ... June 30, 2015. For the second quarter of 2015, the Company ... share, compared to a net loss of $13.4 million, or $0.18 ... six months ended June 30, 2015, the Company reported a net ... to net loss of $25.2 million, or $0.35 loss per share, ...
(Date:7/29/2015)... , July 29, 2015 Immune Pharmaceuticals Inc. ... secured financings of up to $21.5 million through two ... Inc. (NYSE: HTGC ) ("Hercules"), for a term loan ... mutual fund Discover Growth Fund ("Discover"), for the sale ... Preferred Stock ("Preferred Stock") for up to $12 million ...
(Date:7/29/2015)... DALLAS , July 29, 2015 ... Apnea Devices Market by Product, Diagnostic (PSG, Pulse Oximeter), ... Appliances (Mandibular Advancement Device)], End User (Home Care Settings, ... by MarketsandMarkets, this report studies the global Sleep Apnea ... 2020. This market is expected to reach $5.3 Billion ...
Breaking Medicine Technology:Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 2Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 3Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 4Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 5Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 6Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 7Sleep Apnea Devices Market Worth $5.3 Billion by 2020 2Sleep Apnea Devices Market Worth $5.3 Billion by 2020 3Sleep Apnea Devices Market Worth $5.3 Billion by 2020 4
... Phase I data from XL880, Phase II data from ... SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --,Exelixis, Inc. ... investigational compounds XL880 and XL999 will be,presented at the ... is being held June 1 to 5 in Chicago,Illinois. ...
... many as,first-line in secondary stroke prevention , ... presented today at the,16th European Stroke Conference in ... dipyridamole plus ASA,is marketed as Aggrenox® or Asasantin® ... vascular events in patients who had,a TIA or ...
Cached Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... At the presentation of the 2015 ... discussion was focused on research presented by the Journal of Arthroplasty pertaining to ... – like driving. , Results of the study confirm what Santa Rosa Orthopaedics ...
(Date:7/30/2015)... ... 30, 2015 , ... World Breast-Feeding Week (Aug. 1-7) was ... have the nutrition required to grow into healthy adults. Medicationdiscountcard.com supports ... prescription pre-natal vitamins. , Folic Acid , Arguably one of the most important ...
(Date:7/29/2015)... Plano, TX (PRWEB) , ... July 30, 2015 ... ... best content available for their clients, BOC approved provider of online continuing ... six new course offerings to their exclusive Andrews Research and Education Sports Medicine ...
(Date:7/29/2015)... ... July 29, 2015 , ... Avatar Solutions has received official approval from ... Survey. , The CAHPS for PQRS Survey collects information about patients’ experiences ... eligible providers must participate or they will receive a 2% penalty in 2017. At ...
(Date:7/29/2015)... ... July 29, 2015 , ... This past week, ... surrogacy journey from a treasured member of the CARE extended family. , By ... to help intended parents across the globe gain a newfound perspective on surrogacy in ...
Breaking Medicine News(10 mins):Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 3
... Black Americans with lupus have a higher antibody response to ... This may be good news for black Americans with ... the flu vaccine were more likely to experience moderate to ... a greater response. As many as 322,000 adults in ...
... prevents and cures kidney failure in mice sheds light ... potential treatment in people with such illnesses. ... in animals," said study leader Marni J. Falk, M.D., ... at The Children,s Hospital of Philadelphia. "So these striking ...
... sperm quality and who are trying to have children should ... cell phone use appears to increase the level of testosterone ... sperm quality and a decrease in fertility. "Our ... postdoctoral fellow in the Department of Pharmacology and Toxicology and ...
... 19, 2011) The John Theurer Cancer Center at Hackensack ... Promise Foundation to host a skin cancer screening event on ... feature educational information on skin cancer prevention and offer free ... "Skin cancer can be a devastating disease, but ...
... Autnoma de Barcelona researchers have discovered that Viagra drastically ... disease. The research, published in Acta Neuropathologica , ... of the animals after eight days of treatment. Researchers ... out in patients given that the drug is well ...
... Today 16 countries announced new commitments to dramatically reduce ... Global Strategy for Women,s and Children,s Health. ... children,s health is reaching new and encouraging heights. The ... prove that saving the lives of the most vulnerable ...
Cached Medicine News:Health News:Black Americans With Lupus Have Better Response to Flu Vaccine 2Health News:Animal results may pave way to treating rare mitochondrial diseases in children 2Health News:Viagra could reduce multiple sclerosis symptoms 2Health News:New commitments to save women and children 2Health News:New commitments to save women and children 3Health News:New commitments to save women and children 4Health News:New commitments to save women and children 5Health News:New commitments to save women and children 6Health News:New commitments to save women and children 7Health News:New commitments to save women and children 8
... of a 384 Well Plate at Once , ... plates, you need a pipettor that can adapt ... you get with our 16-channel Impact pipettor., Available ... innovation was specifically designed to allow you to ...
... and Alliance Catheter Delivery System ... introduction of catheters or devices ... a superior approach. These introducers ... peel-away introducer performance with a ...
The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
... System combines low-profile, high radial force, and excellent ... compatible stent system provides 6F sheath / 8F ... 10.0 mm). Now, with longer stents available, the ... lengths (28, 38, 56, 80 and 100 mm) ...
Medicine Products: